Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery and in vitro insight

References

• Kirby, B. J., Collier, A. C., Kharasch, E. D., Dixit, V., Desai, P., Whittington, D., Thummel, K. E., & Unadkat, J. D. (2011). Complex drug interactions of HIV protease inhibitors 2: In vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 39(12), 2329–2337. https://doi.org/10.1124/dmd.111.038646
   PubMed Web of Science ®Google Scholar
• Gote, V., Sharma, A. D., & Pal, D. (2021). Hyaluronic acid-targeted stimuli-sensitive nanomicelles co-encapsulating paclitaxel and ritonavir to overcome multi-drug resistance in metastatic breast cancer and triple-negative breast cancer cells. International Journal of Molecular Sciences, 22(3), 1257. https://doi.org/10.3390/ijms22031257
   PubMed Web of Science ®Google Scholar
• Bardelmeijer, H. A., Ouwehand, M., Buckle, T., Huisman, M. T., Schellens, J. H. M., Beijnen, J. H., & van Tellingen, O. (2002). Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by Ritonavir. Cancer Research, 62(21), 6158–6164.
   PubMed Web of Science ®Google Scholar
• Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J. F., Gibbons, S. E., Breckenridge, A. M., & Back, D. J. (1997). Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS (London, England), 11(4), F29–F33.
   PubMed Web of Science ®Google Scholar
• Akinleye, A., & Rasool, Z. (2019). Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology & Oncology, 12(1), 1–13. https://doi.org/10.1186/s13045-019-0779-5
   PubMed Web of Science ®Google Scholar
• Almahmoud, S., & Zhong, H. A. (2019). Molecular modeling studies on the binding mode of the PD-1/PD-L1 complex inhibitors. International Journal of Molecular Sciences, 20(18), 4654. https://doi.org/10.3390/ijms20184654
   PubMed Web of Science ®Google Scholar
• Bandiera, E., Todeschini, P., Romani, C., Zanotti, L., Erba, E., Colmegna, B., Bignotti, E., Santin, A. D., Sartori, E., Odicino, F. E., Pecorelli, S., Tassi, R. A., & Ravaggi, A. (2016). The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. Oncology Letters, 12(4), 2493–2500. https://doi.org/10.3892/ol.2016.5008
   PubMed Web of Science ®Google Scholar
• Batchu, R. B., Gruzdyn, O. V., Bryant, C. S., Qazi, A. M., Kumar, S., Chamala, S., Kung, S. T., Sanka, R. S., Puttagunta, U. S., Weaver, D. W., & Gruber, S. A. (2014). Ritonavir-mediated induction of apoptosis in pancreatic cancer occurs via the RB/E2F-1 and AKT pathways. Pharmaceuticals (Basel, Switzerland), 7(1), 46–57. https://doi.org/10.3390/ph7010046
   PubMedGoogle Scholar
• Bukowski, K., Kciuk, M., & Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. International Journal of Molecular Sciences, 21(9), 3233. https://doi.org/10.3390/ijms21093233
   PubMed Web of Science ®Google Scholar
• Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015). HDAC8: A multifaceted target for therapeutic interventions. Trends in Pharmacological Sciences, 36(7), 481–492. https://doi.org/10.1016/j.tips.2015.04.013
   PubMed Web of Science ®Google Scholar
• Chou, T. C. (2010). Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Research, 70(2), 440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Chow, W. A., Jiang, C., & Guan, M. (2009). Anti-HIV drugs for cancer therapeutics: Back to the future? Lancet Oncology. 10(1), 61–71. https://doi.org/10.1016/S1470-2045(08)70334-6
   PubMed Web of Science ®Google Scholar
• Chu, C. M., Cheng, V. C. C., Hung, I. F. N., Wong, M. M. L., Chan, K. H., & Chan, K. S. (2004). Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax, 59(3), 252–256. https://doi.org/10.1136/thorax.2003.012658
   PubMed Web of Science ®Google Scholar
• da Silva, T. U., Pougy K de, C., Albuquerque, M. G., da Silva Lima, C. H., & Machado S de, P. (2020). Development of parameters compatible with the CHARMM36 force field for [Fe4S4]2+ clusters and molecular dynamics simulations of adenosine-5’-phosphosulfate reductase in GROMACS 2019. Journal of Biomolecular Structure and Dynamics, 40(8), 1–11.
   Google Scholar
• D'Abramo, C. M., & Archambault, J. (2011). Small molecule inhibitors of human papillomavirus protein – Protein interactions. The Open Virology Journal, 5(1), 80–95. https://doi.org/10.2174/1874357901105010080
   PubMedGoogle Scholar
• De Clercq, E. (2004). Antiviral drugs in current clinical use. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology, 30(2), 115–133. https://doi.org/10.1016/j.jcv.2004.02.009
   PubMed Web of Science ®Google Scholar
• Eagling, V. A., Back, D. J., & Barry, M. G. (1997). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology, 44(2), 190–194. https://doi.org/10.1046/j.1365-2125.1997.00644.x
   PubMed Web of Science ®Google Scholar
• Ekroos, M., & Sjögren, T. (2006). Structural basis for ligand promiscuity in cytochrome P450 3A4. Proceedings of the National Academy of Sciences of the United States of America, 103(37), 13682–13687. https://doi.org/10.1073/pnas.0603236103
   PubMed Web of Science ®Google Scholar
• Esposito, V., Palescandolo, E., Spugnini, E. P., Montesarchio, V., De Luca, A., Cardillo, I., Cortese, G., Baldi, A., & Chirianni, A. (2006). Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(8), 2634–2639. https://doi.org/10.1158/1078-0432.CCR-05-2188
   PubMed Web of Science ®Google Scholar
• Flexner, C. (1998). HIV-protease inhibitors. The New England Journal of Medicine, 338(18), 1281–1292. https://doi.org/10.1056/NEJM199804303381808
   PubMed Web of Science ®Google Scholar
• Forli, S., Huey, R., Pique, M. E., Sanner, M. F., Goodsell, D. S., & Olson, A. J. (2016). Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nature Protocols, 11(5), 905–919. https://doi.org/10.1038/nprot.2016.051
   PubMed Web of Science ®Google Scholar
• Gaedicke, S., Firat-Geier, E., Constantiniu, O., Lucchiari-Hartz, M., Freudenberg, M., Galanos, C., & Niedermann, G. (2002). Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: Induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Research, 62(23), 6901–6908.
   PubMed Web of Science ®Google Scholar
• Gantt, S., Casper, C., & Ambinder, R. F. (2013). Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Current Opinion in Oncology, 25(5), 495–502. https://doi.org/10.1097/CCO.0b013e328363dfee
   PubMed Web of Science ®Google Scholar
• Ghosh, D., Griswold, J., Erman, M., & Pangborn, W. (2009). Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature, 457(7226), 219–223. https://doi.org/10.1038/nature07614
   PubMed Web of Science ®Google Scholar
• González de Requena, D., Gallego, O., de Mendoza, C., Corral, A., Jiménez-Nácher, I., & Soriano, V. (2003). Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. AIDS Research and Human Retroviruses, 19(6), 457–459. https://doi.org/10.1089/088922203766774496
   PubMed Web of Science ®Google Scholar
• Grosdidier, A., Zoete, V., & Michielin, O. (2011). SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Research, 39(Web Server issue), W270–W277. https://doi.org/10.1093/nar/gkr366
   PubMed Web of Science ®Google Scholar
• Guedes, I. A., de Magalhães, C. S., & Dardenne, L. E. (2014). Receptor–ligand molecular docking. Biophysical Reviews, 6(1), 75–87. https://doi.org/10.1007/s12551-013-0130-2
   PubMedGoogle Scholar
• Hampson, L., Kitchener, H. C., & Hampson, IN. (2006). Specific HIV protease inhibitors inhibit the ability of Hpv16 E6 to degrade P53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antiviral Therapy, 11(6), 813–825. https://doi.org/10.1177/135965350601100607
   PubMed Web of Science ®Google Scholar
• Hsu, A., Granneman, G. R., & Bertz, R. J. (1998). Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics, 35(4), 275–291. https://doi.org/10.2165/00003088-199835040-00002
   PubMed Web of Science ®Google Scholar
• Huang, H., Feng, Y.-L., Wan, T., Zhang, Y.-N., Cao, X.-P., Huang, Y.-W., Xiong, Y., Huang, X., Zheng, M., Li, Y.-F., Li, J.-D., Chen, G.-D., Li, H., Chen, Y.-L., Ma, L.-G., Yang, H.-Y., Li, L., Yao,S.-Z.,Ye, ˙˙˙ & Liu, J.-H. (2021). Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: The STARS phase 3 randomized clinical trial. JAMA Oncology, 7(3), 361–369. https://doi.org/10.1001/jamaoncol.2020.7168
   PubMed Web of Science ®Google Scholar
• Huang, P.-J., Chiu, C.-C., Hsiao, M.-H., Yow, J., Tzang, B.-S., & Hsu, T.-C. (2021). Potential of antiviral drug oseltamivir for the treatment of liver cancer. International Journal of Oncology, 59(6), 1–21. https://doi.org/10.3892/ijo.2021.5289
   Web of Science ®Google Scholar
• Ikezoe, T., Hisatake, Y., Takeuchi, T., Ohtsuki, Y., Yang, Y., Said, J. W., Taguchi, H., & Koeffler, H. P. (2004). HIV-1 protease inhibitor. Cancer Research, 64(20), 7426–7431. https://doi.org/10.1158/0008-5472.CAN-03-2677
   PubMedGoogle Scholar
• Isono, M., Sato, A., Asano, T., Okubo, K., & Asano, T. (2018). Delanzomib interacts with ritonavir synergistically to cause endoplasmic reticulum stress in renal cancer cells. Anticancer Research, 38(6), 3493–3500. https://doi.org/10.21873/anticanres.12620
   PubMed Web of Science ®Google Scholar
• Jarada, T. N., Rokne, J. G., & Alhajj, R. (2020). A review of computational drug repositioning: Strategies, approaches, opportunities, challenges, and directions. Journal of Cheminformatics, 12(1), 1–23. https://doi.org/10.1186/s13321-020-00450-7
   PubMed Web of Science ®Google Scholar
• Jász, Á., Rák, Á., Ladjánszki, I., & Cserey, G. (2019). Optimized GPU implementation of Merck molecular force field and universal force field. Journal of Molecular Structure. 1188, 227–233. https://doi.org/10.1016/j.molstruc.2019.04.007
   Web of Science ®Google Scholar
• Jejurikar, B. L., & Rohane, S. H. (2021). Drug designing in discovery studio. Asian J Res Chem, 14(2), 135–138.
   Google Scholar
• Jourdan, J. P., Bureau, R., Rochais, C., & Dallemagne, P. (2020). Drug repositioning: A brief overview. The Journal of Pharmacy and Pharmacology, 72(9), 1145–1151. https://doi.org/10.1111/jphp.13273
   PubMed Web of Science ®Google Scholar
• Justesen, U. S., Levring, A. M., Thomsen, A., Lindberg, J. A., Pedersen, C., & Tauris, P. (2003). Low-dose indinavir in combination with low-dose ritonavir: Steady-state pharmacokinetics and long-term clinical outcome follow-up. HIV Medicine, 4(3), 250–254. https://doi.org/10.1046/j.1468-1293.2003.00153.x
   PubMedGoogle Scholar
• Kappert, K., Caglayan, E., Bäumer, A. T., Südkamp, M., Fätkenheuer, G., & Rosenkranz, S. (2004). Ritonavir exhibits anti-atherogenic properties on vascular smooth muscle cells. AIDS, 18(3), 403–411.
   PubMed Web of Science ®Google Scholar
• Kumar, S., Bryant, C. S., Chamala, S., Qazi, A., Seward, S., Pal, J., Steffes, C. P., Weaver, D. W., Morris, R., Malone, J. M., Shammas, M. A., Prasad, M., & Batchu, R. B. (2009). Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Molecular Cancer, 8(26), 26–21. https://doi.org/10.1186/1476-4598-8-26
   PubMedGoogle Scholar
• Kwon, Y. J., Shin, S., & Chun, Y. J. (2021). Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. Archives of Pharmacal Research, 44(1), 63–83. https://doi.org/10.1007/s12272-021-01306-w
   PubMed Web of Science ®Google Scholar
• Lee, A., Saito, E., Ekins, S., & McMurtray, A. (2019). Extracellular binding of indinavir to matrix metalloproteinase-2 and the alpha-7-nicotinic acetylcholine receptor: Implications for use in cancer treatment. Heliyon, 5(9), e02526. https://doi.org/10.1016/j.heliyon.2019.e02526
   PubMed Web of Science ®Google Scholar
• Lee, J. Y., Lee, H. T., Shin, W., Chae, J., Choi, J., Kim, S. H., Lim, H., Won Heo, T., Park, K. Y., Lee, Y. J., Ryu, S. E., Son, J. Y., Lee, J. U., & Heo, Y.-S. (2016). Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nature Communications, 7(1), 13354–13310. https://doi.org/10.1038/ncomms13354
   PubMedGoogle Scholar
• Lewis, R. T., Bode, C. M., Choquette, D. M., Potashman, M., Romero, K., Stellwagen, J. C., Teffera, Y., Moore, E., Whittington, D. A., Chen, H., Epstein, L. F., Emkey, R., Andrews, P. S., Yu, V. L., Saffran, D. C., Xu, M., Drew, A., Merkel, P., Szilvassy, S., & Brake, R. L, RCSB PDB - 4FOC. (2012). The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. Journal of Medicinal Chemistry, 55(14), 6523–6540. https://doi.org/10.1021/jm3005866
   PubMed Web of Science ®Google Scholar
• Li, H., & Li, C. (2010). Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein. Journal of Computational Chemistry, 31(10), 2014–2022.
   PubMed Web of Science ®Google Scholar
• Li, H., Liu, T., Wu, X., & Chen, Q. (2020). An optimized VMD method and its applications in bearing fault diagnosis. Measurement, 166, 108185. https://doi.org/10.1016/j.measurement.2020.108185
   Web of Science ®Google Scholar
• Li, W., Sparidans, R. W., Wang, Y., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2019). Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V, 136, 120–130. https://doi.org/10.1016/j.ejpb.2019.01.016
   PubMed Web of Science ®Google Scholar
• Longatto-Filho, A., Pinheiro, C., Martinho, O., Moreira, M. A., Ribeiro, L. F., Queiroz, G. S., Schmitt, F. C., Baltazar, F., & Reis, R. M. (2009). Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer, 9(1), 212–218. https://doi.org/10.1186/1471-2407-9-212
   PubMedGoogle Scholar
• Mabuchi, S., Isohashi, F., Yoshioka, Y., Temma, K., Takeda, T., Yamamoto, T., Enomoto, T., Morishige, K., Inoue, T., & Kimura, T. (2010). Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 20(5), 834–840. https://doi.org/10.1111/IGC.0b013e3181dcadd1
   PubMed Web of Science ®Google Scholar
• Majumder, R., & Mandal, M. (2022). Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: An in silico docking and molecular dynamics simulation approach. Journal of Biomolecular Structure & Dynamics, 40(2), 696–711. https://doi.org/10.1080/07391102.2020.1817787
   PubMed Web of Science ®Google Scholar
• Makinson, A., Pujol, J. L., Le Moing, V., Peyriere, H., & Reynes, J. (2010). Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 5(4), 562–571. https://doi.org/10.1097/JTO.0b013e3181d3ccf2
   PubMed Web of Science ®Google Scholar
• Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori-Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J. (2018). Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Medicine, 7(6), 2641–2653. https://doi.org/10.1002/cam4.1517
   PubMed Web of Science ®Google Scholar
• Metzler, W. J., Bajorath, J., Fenderson, W., Shaw, S. Y., Constantine, K. L., Naemura, J., Leytze, G., Peach, R. J., Lavoie, T. B., Mueller, L., & Linsley, P. S. (1997). Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nature Structural Biology, 4(7), 527–531. https://doi.org/10.1038/nsb0797-527
   PubMedGoogle Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Nair, H. B., Luthra, R., Kirma, N., Liu, Y.-G., Flowers, L., Evans, D., & Tekmal, R. R. (2005). Induction of aromatase expression in cervical carcinomas: Effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Research, 65(23), 11164–11173. https://doi.org/10.1158/0008-5472.CAN-05-1087
   PubMed Web of Science ®Google Scholar
• Nakagawa, S., Yoshikawa, H., Yasugi, T., Kimura, M., Kawana, K., Matsumoto, K., Yamada, M., Onda, T., & Taketani, Y. (2000). Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. Journal of Medical Virology, 62(2), 251–256. https://doi.org/10.1002/1096-9071(200010)62:2<251::AID-JMV18>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Okubo, K., Isono, M., Asano, T., & Sato, A. (2019). Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells. Anticancer Research, 39(11), 5891–5901. https://doi.org/10.21873/anticanres.13793
   PubMed Web of Science ®Google Scholar
• Okunade, K. S. (2020). Human papillomavirus and cervical cancer. Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology, 40(5), 602–608. https://doi.org/10.1080/01443615.2019.1634030
   PubMedGoogle Scholar
• Páll, S., Zhmurov, A., Bauer, P., Abraham, M., Lundborg, M., Gray, A., Hess, B., & Lindahl, E. (2020). Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS. The Journal of Chemical Physics, 153(13), 134110. https://doi.org/10.1063/5.0018516
   PubMed Web of Science ®Google Scholar
• Patel, A. K., Patel, K. K., Patel, J. K., Sharma, R. L., & Ranjan, R. R. (2006). Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-year follow-up. Journal of Acquired Immune Deficiency Syndromes (1999), 43(1), 123–126. https://doi.org/10.1097/01.qai.0000230522.86964.5d
   PubMed Web of Science ®Google Scholar
• PDB - 5VCC, R. C. S. B., & Sevrioukova, I. F. (2017). High-level production and properties of the cysteine-depleted cytochrome P450 3A4. Biochemistry, 56(24), 3058–3067. https://doi.org/10.1021/acs.biochem.7b00334
   PubMed Web of Science ®Google Scholar
• Pfab, C., Schnobrich, L., Eldnasoury, S., Gessner, A., & El-Najjar, N. (2021). Repurposing of antimicrobial agents for cancer therapy: What do we know? Cancers (Basel), 13(13), 3193. https://doi.org/10.3390/cancers13133193
   PubMed Web of Science ®Google Scholar
• Poirson, J., Suarez, I. P., Cousido-Siah, A., Forster, A., Chebaro, Y., Mitschler, A., Straub, M., Altschuh, D., Podjarny, A., Trave, G., & Masson, M. (2017). RCSB PDB – 6SJA: Deciphering de molecular and structural interaction between IRF3 and HPV16 E6. (To be published)
   Google Scholar
• Qiu, Y., Maione, F., Capano, S., Meda, C., Picconi, O., Brundu, S., Pisacane, A., Sapino, A., Palladino, C., Barillari, G., Monini, P., Bussolino, F., Ensoli, B., Sgadari, C., & Giraudo, E. (2020). HIV protease inhibitors block HPV16-induced murine cervical carcinoma and promote vessel normalization in association with MMP-9 inhibition and TIMP-3 induction. Molecular Cancer Therapeutics, 19(12), 2476–2489. https://doi.org/10.1158/1535-7163.MCT-20-0055
   PubMed Web of Science ®Google Scholar
• Quiroga, I., & Scior, T. (2019). Induced fit for cytochrome P450 3A4 based on molecular dynamics. Admet & Dmpk, 7(4), 252–266. https://doi.org/10.5599/admet.729
   PubMedGoogle Scholar
• Rana, K. Z., & Dudley, M. N. (1999). Human immunodeficiency virus protease inhibitors (1999). Pharmacotherapy, 19(1), 35–59. https://doi.org/10.1592/phco.19.1.35.30513
   PubMed Web of Science ®Google Scholar
• Rauf, M. A., Zubair, S., & Azhar, A. (2015). Ligand docking and binding site analysis with pymol and autodock/vina. International Journal of Basic and Applied Sciences, 4(2), 168–177. https://doi.org/10.14419/ijbas.v4i2.4123
   Google Scholar
• Rauschenbach, L., Wieland, A., Reinartz, R., Kebir, S., Till, A., Darkwah Oppong, M., Dobersalske, C., Ullrich, V., Ahmad, A., Jabbarli, R., Pierscianek, D., Fröhlich, H., Simon, M., Brüstle, O., Sure, U., Glas, M., & Scheffler, B. (2020). Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma. European Journal of Cancer (Oxford, England : 1990), 140, 130–139. https://doi.org/10.1016/j.ejca.2020.09.017
   PubMed Web of Science ®Google Scholar
• Reichheld, A., Mukherjee, P. K., Rahman, S. M., David, K. V., & Pricilla, R. A. (2020). Prevalence of cervical cancer screening and awareness among women in an urban community in South India–A Cross sectional study. Annals of Global Health, 86(1), 30.
   PubMed Web of Science ®Google Scholar
• Reis, G., Moreira Silva, E. A. D. S., Medeiros Silva, D. C., Thabane, L., Singh, G., Park, J. J. H., Forrest, J. I., Harari, O., Quirino Dos Santos, C. V., Guimarães de Almeida, A. P. F., Figueiredo Neto, A. D. d., Savassi, L. C. M., Milagres, A. C., Teixeira, M. M., Simplicio, M. I. C., Ribeiro, L. B., Oliveira, R., & Mills, E. J. (2021). Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: The together randomized clinical trial. JAMA Network Open, 4(4), e216468–e216468. https://doi.org/10.1001/jamanetworkopen.2021.6468
   Web of Science ®Google Scholar
• Rock, B. M., Hengel, S. M., Rock, D. A., Wienkers, L. C., & Kunze, K. L. (2014). Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Molecular Pharmacology, 86(6), 665–674. https://doi.org/10.1124/mol.114.094862
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona, C., & Ingelman-Sundberg, M. (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene, 25(11), 1679–1691. https://doi.org/10.1038/sj.onc.1209377
   PubMed Web of Science ®Google Scholar
• Rudrapal, M., Khairnar, S. J., & Jadhav, A. G. (2020). Drug repurposing (DR): An emerging approach in drug discovery. In F. A. Badria (Ed.) Drug repurposing – Hypothesis, molecular aspects and therapeutic applications. IntechOpen.
   Google Scholar
• Seidel, J. A., Otsuka, A., & Kabashima, K. (2018). Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Frontiers in Oncology, 8, 86. https://doi.org/10.3389/fonc.2018.00086
   PubMed Web of Science ®Google Scholar
• Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012). Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 15–31. https://doi.org/10.1517/14728222.2011.648617
   PubMed Web of Science ®Google Scholar
• Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., Palladino, C., Leone, P., Bugarini, R., Malavasi, L., Cafaro, A., Falchi, M., Valdembri, D., Rezza, G., Bussolino, F., Monini, P., & Ensoli, B. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Medicine, 8(3), 225–232. https://doi.org/10.1038/nm0302-225
   PubMed Web of Science ®Google Scholar
• Shih, W. L., Fang, C. T., & Chen, P. J. (2014). Anti-viral treatment and cancer control. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur le Cancer, 193, 269–290. https://doi.org/10.1007/978-3-642-38965-8_14
   PubMedGoogle Scholar
• Srirangam, A., Milani, M., Mitra, R., Guo, Z., Rodriguez, M., Kathuria, H., Fukuda, S., Rizzardi, A., Schmechel, S., Skalnik, D. G., Pelus, L. M., & Potter, D. A. (2011). The HIV protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. Journal of Thoracic Oncology, 6(4), 661–670. https://doi.org/10.1097/JTO.0b013e31820c9e3c
   PubMed Web of Science ®Google Scholar
• Srirangam, A., Mitra, R., Wang, M., Gorski, J. C., Badve, S., Baldridge, L., Hamilton, J., Kishimoto, H., Hawes, J., Li, L., Orschell, C. M., Srour, E. F., Blum, J. S., Donner, D., Sledge, G. W., Nakshatri, H., & Potter, D. A. (2006). Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(6), 1883–1896.
   PubMed Web of Science ®Google Scholar
• Taja-Chayeb, L., Chavez-Blanco, A., Martínez-Tlahuel, J., González-Fierro, A., Candelaria, M., Chanona-Vilchis, J., Robles, E., & Dueñas-Gonzalez, A. (2006). Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell International, 6(1), 22–21. https://doi.org/10.1186/1475-2867-6-22
   PubMedGoogle Scholar
• Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., Gao, S., Wang, Z., Shi, Y., Yang, F., Gao, G. F., & Yan, J. (2017). An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 8(1), 14369–14310. https://doi.org/10.1038/ncomms14369
   PubMed Web of Science ®Google Scholar
• Tian, W., Chen, C., Lei, X., Zhao, J., & Liang, J. (2018). CASTp 3.0: Computed atlas of surface topography of proteins. Nucleic Acids Research, 46(W1), W363–W367. https://doi.org/10.1093/nar/gky473
   PubMed Web of Science ®Google Scholar
• Tolbert, M., Morgan, C. E., Pollum, M., Crespo-Hernández, C. E., Li, M.-L., Brewer, G., & Tolbert, B. S. (2017). HnRNP A1 alters the structure of a conserved enterovirus IRES domain to stimulate viral translation. Journal of Molecular Biology, 429(19), 2841–2858. https://doi.org/10.1016/j.jmb.2017.06.007
   PubMed Web of Science ®Google Scholar
• Tuli, H. S., Sak, K., Gupta, D. S., Kaur, G., Aggarwal, D., Chaturvedi Parashar, N., Choudhary, R., Yerer, M. B., Kaur, J., Kumar, M., Garg, V. K., & Sethi, G. (2021). Anti-inflammatory and anticancer properties of birch bark-derived betulin: Recent developments. Plants, 10(12), 2663. https://doi.org/10.3390/plants10122663
   Google Scholar
• Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2021). Gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation, 17(10), 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645
   PubMed Web of Science ®Google Scholar
• Vermunt, M. A. C., Robbrecht, D. G. J., Devriese, L. A., Janssen, J. M., Thijssen, B., Keessen, M., van Eijk, M., Kessels, R., Eskens, F. A. L. M., Beijnen, J. H., Mehra, N., & Bergman, A. M. (2021). ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. Cancer Reports (Hoboken, N.J.), 4(4), e1367. https://doi.org/10.1002/cnr2.1367
   PubMedGoogle Scholar
• Vermunt, M. A. C., van der Heijden, L. T., Hendrikx, J. J. M. A., Schinkel, A. H., de Weger, V. A., van der Putten, E., van Triest, B., Bergman, A. M., & Beijnen, J. H. (2021). Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemotherapy and Pharmacology, 87(6), 855–869. https://doi.org/10.1007/s00280-021-04259-5
   PubMed Web of Science ®Google Scholar
• von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Duan, S. X., Fogelman, S. M., Daily, J. P., Harmatz, J. S., & Shader, R. I. (1998). Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. Journal of Clinical Pharmacology, 38(2), 106–111. https://doi.org/10.1002/j.1552-4604.1998.tb04398.x
   PubMed Web of Science ®Google Scholar
• Wang, E., Sun, H., Wang, J., Wang, Z., Liu, H., Zhang, J. Z., & Hou, T. (2019). End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chemical Reviews, 119(16), 9478–9508. https://doi.org/10.1021/acs.chemrev.9b00055
   PubMed Web of Science ®Google Scholar
• Webb, T. R., Slavish, J., George, R. E., Look, A. T., Xue, L., Jiang, Q., Cui, X., Rentrop, W. B., & Morris, S. W. (2009). Anaplastic lymphoma kinase: Role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Review of Anticancer Therapy, 9(3), 331–356. https://doi.org/10.1586/14737140.9.3.331
   PubMed Web of Science ®Google Scholar
• Yan, X. E., & Yun, C. H. (2021). RCSB PDB – 5GRN: Crystal structure of PDGFRA in complex with WQ-C-159 (To be published)
   Google Scholar
• Yu, H., Hendrikx, J. J., Rottenberg, S., Schellens, J. H., Beijnen, J. H., & Huitema, A. D. (2016). Development of a tumour growth inhibition model to elucidate the effects of ritonavir on intratumoural metabolism and anti-tumour effect of docetaxel in a mouse model for hereditary breast cancer. The AAPS Journal, 18(2), 362–371. https://doi.org/10.1208/s12248-015-9838-1
   PubMed Web of Science ®Google Scholar
• Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 125(6), 1137–1149. https://doi.org/10.1016/j.cell.2006.05.013
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020). Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy, 5(1), 1–25. https://doi.org/10.1038/s41392-020-00213-8
   PubMed Web of Science ®Google Scholar
• Zhu, H., Luo, H., Zhang, W., Shen, Z., Hu, X., & Zhu, X. (2016). Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy, 10, 1885–1895.
   PubMed Web of Science ®Google Scholar